5:18 PM
Mar 12, 2012
 |  BC Extra  |  Clinical News

Pfizer: Prevnar 13 immunogenic in children, adolescents

Pfizer Inc. (NYSE:PFE) said Prevnar 13 met all study endpoints in a Phase III trial to prevent pneumococcal disease in healthy children aged 5-17 years old. The pharma said the pneumococcal vaccine demonstrated immunogenicity at one month post-vaccination regardless of prior vaccination with Prevnar ( PCV7), the pharma's vaccine containing seven...

Read the full 248 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >